US Industry Welcomes Nomination Of Califf To FDA Helm For A Second Time
Cardiologist Previously Served As FDA Commissioner Between 2016 and 2017
The US off-patent industry has welcomed the news that Robert Califf looks likely to serve a second term as US Food and Drug Administration commissioner, after his nomination by US President Joe Biden.
You may also be interested in...
Bills to reign in petitions, pay-for-delay, product hopping, and patent thickets clear House Judiciary Committee. Legislation may have better shot at enactment this time around given bipartisan support in both House and Senate Committees.
Members of Congress, companies and government agencies want the Patent Office to change policies that they say impede generic drug competition. The latest effort is focused on PTO’s discretionary denial of inter partes review petitions, which is the subject of a bipartisan congressional letter and cert petition to the US Supreme Court.
Post-warning letter meetings for manufacturing issues and updates to the complex product meeting process are included in the user fee extension agreement.